Vicapsys Life Sciences, Inc.
VICP
$1.77
$0.5039.37%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 66.46% | 70.81% | 53.45% | 63.80% | 15.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.82% | 68.92% | 51.34% | 62.83% | 13.20% |
| Operating Income | -64.82% | -68.92% | -51.34% | -62.83% | -13.20% |
| Income Before Tax | -24.78% | -37.33% | -26.12% | -20.03% | -81.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.78% | -37.33% | -26.12% | -20.03% | -81.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.78% | -37.33% | -26.12% | -20.03% | -81.16% |
| EBIT | -64.82% | -68.92% | -51.34% | -62.83% | -13.20% |
| EBITDA | 19.30% | -12.02% | -23.92% | -66.05% | -13.97% |
| EPS Basic | -21.41% | -30.49% | -16.92% | -5.28% | -47.96% |
| Normalized Basic EPS | -68.61% | -90.16% | -64.93% | -60.61% | 0.00% |
| EPS Diluted | -21.41% | -30.49% | -3.54% | 16.50% | -7.21% |
| Normalized Diluted EPS | -68.61% | -90.16% | -64.93% | -60.61% | 0.00% |
| Average Basic Shares Outstanding | 0.05% | 2.54% | 6.72% | 13.90% | 24.08% |
| Average Diluted Shares Outstanding | 0.05% | 2.54% | 6.72% | 13.90% | 24.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |